| Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial … SB Cohen, P Emery, MW Greenwald, M Dougados, RA Furie, ... Arthritis & Rheumatism 54 (9), 2793-2806, 2006 | 2295 | 2006 |
| A phase III, randomized, placebo‐controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus R Furie, M Petri, O Zamani, R Cervera, DJ Wallace, D Tegzová, ... Arthritis & Rheumatism 63 (12), 3918-3930, 2011 | 1826 | 2011 |
| Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study BH Rovin, R Furie, K Latinis, RJ Looney, FC Fervenza, ... Arthritis & Rheumatism 64 (4), 1215-1226, 2012 | 1566 | 2012 |
| Trial of anifrolumab in active systemic lupus erythematosus EF Morand, R Furie, Y Tanaka, IN Bruce, AD Askanase, C Richez, ... New England Journal of Medicine 382 (3), 211-221, 2020 | 1122 | 2020 |
| Anifrolumab, an anti–interferon‐α receptor monoclonal antibody, in moderate‐to‐severe systemic lupus erythematosus R Furie, M Khamashta, JT Merrill, VP Werth, K Kalunian, P Brohawn, ... Arthritis & rheumatology 69 (2), 376-386, 2017 | 935 | 2017 |
| Two-year, randomized, controlled trial of belimumab in lupus nephritis R Furie, BH Rovin, F Houssiau, A Malvar, YKO Teng, G Contreras, ... New England Journal of Medicine 383 (12), 1117-1128, 2020 | 825 | 2020 |
| A short course of BG9588 (anti–CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis DT Boumpas, R Furie, S Manzi, GG Illei, DJ Wallace, JE Balow, ... Arthritis & Rheumatism 48 (3), 719-727, 2003 | 742 | 2003 |
| A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosus DJ Wallace, W Stohl, RA Furie, JR Lisse, JD McKay, JT Merrill, MA Petri, ... Arthritis Care & Research: Official Journal of the American College of …, 2009 | 689 | 2009 |
| The immune cell landscape in kidneys of patients with lupus nephritis A Arazi, DA Rao, CC Berthier, A Davidson, Y Liu, PJ Hoover, A Chicoine, ... Nature immunology 20 (7), 902-914, 2019 | 643 | 2019 |
| Novel paradigms in systemic lupus erythematosus T Dörner, R Furie The Lancet 393 (10188), 2344-2358, 2019 | 571 | 2019 |
| Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study M Khamashta, JT Merrill, VP Werth, R Furie, K Kalunian, GG Illei, ... Annals of the rheumatic diseases 75 (11), 1909-1916, 2016 | 523 | 2016 |
| Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial DJ Wallace, RA Furie, Y Tanaka, KC Kalunian, M Mosca, MA Petri, ... The Lancet 392 (10143), 222-231, 2018 | 515 | 2018 |
| Novel evidence‐based systemic lupus erythematosus responder index RA Furie, MA Petri, DJ Wallace, EM Ginzler, JT Merrill, W Stohl, ... Arthritis Care & Research: Official Journal of the American College of …, 2009 | 509 | 2009 |
| Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial RA Furie, EF Morand, IN Bruce, S Manzi, KC Kalunian, EM Vital, TL Ford, ... The Lancet Rheumatology 1 (4), e208-e219, 2019 | 416 | 2019 |
| Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined … S Manzi, J Sánchez-Guerrero, JT Merrill, R Furie, D Gladman, SV Navarra, ... Annals of the rheumatic diseases 71 (11), 1833-1838, 2012 | 409 | 2012 |
| High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis R Kokkola, E Sundberg, AK Ulfgren, K Palmblad, J Li, H Wang, L Ulloa, ... Arthritis & Rheumatism 46 (10), 2598-2603, 2002 | 401 | 2002 |
| Efficacy and safety of abatacept in lupus nephritis: a twelve‐month, randomized, double‐blind study R Furie, K Nicholls, TT Cheng, F Houssiau, R Burgos‐Vargas, SL Chen, ... Arthritis & rheumatology 66 (2), 379-389, 2014 | 380 | 2014 |
| Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double‐blind, phase III study EF Mysler, AJ Spindler, R Guzman, M Bijl, D Jayne, RA Furie, ... Arthritis & Rheumatism 65 (9), 2368-2379, 2013 | 365 | 2013 |
| EULAR recommendations for the management of systemic lupus erythematosus: 2023 update A Fanouriakis, M Kostopoulou, J Andersen, M Aringer, L Arnaud, SC Bae, ... Annals of the rheumatic diseases 83 (1), 15-29, 2024 | 352 | 2024 |
| Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus R Furie, W Stohl, EM Ginzler, M Becker, N Mishra, W Chatham, JT Merrill, ... Arthritis research & therapy 10, 1-15, 2008 | 301 | 2008 |
